Murat Güzel

Dr. Murat Güzel


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 December 2013 in Surgery Today
Verified
Journal Article
Closed access
PDF file
MGMurat Güzel
Murat Güzel
ESErdoğan Mütevelli Sözüer
Erdoğan Mütevelli Sözüer
ÖSÖmer Salt
Ömer Salt
IIIbrahim Ikizceli
Ibrahim Ikizceli
OAOkhan Akdur
Okhan Akdur
CYCevat Yazıcı
Cevat Yazıcı

28 June 2021 in Angiology
Verified
Journal Article
Closed access
PDF file
SGSelim Görgün
Selim Görgün
ŞCŞener Cindoruk
Şener Cindoruk
EÖEmre Özgen
Emre Özgen
MYMetin Yadigaroğlu
Metin Yadigaroğlu
MDMehmet Tevfik Demir
Mehmet Tevfik Demir
MGMurat Güzel
Murat Güzel
We aimed to evaluate whether there was a relationship between endocan (human endothelial cell-specific molecule-1) levels and disease prognosis in patients who presented to the emergency department with coronavirus disease 2019 (COVID-19). A total of 60 patients with COVID-19 who were hospitalized from the emergency department to clinical wards and a control group consisting of healthy adult individuals (n = 28), were included in the study. The majority (93.3%) of the patients were discharged after recovery; 6.7% died. The median endocan value was 243.5 ng/mL in the patient group versus 201.5 ng/mL in the control group (P = .002). The median endocan level was 240.5 ng/mL in those discharged with recovery and 558 ng/mL in those who died (P = .001). There was no significant relationship in hospitalization duration, sex, tomography findings, and clinical outcomes. A 202 ng/mL serum endocan level had 86.7% sensitivity and 50% specificity for COVID-19. Serum endocan levels may be a useful biomarker both for the diagnosis of COVID-19 and to predict mortality.

1 September 2016 in Turkish Journal of Emergency Medicine
Verified
Journal Article
Open access
MGMurat Güzel
Murat Güzel
HAHandan Akar
Handan Akar
AEAli Kemal Erenler
Ali Kemal Erenler
ABAhmet Baydin
Ahmet Baydin
AKAbdulcelil Kayabas
Abdulcelil Kayabas
Various manifestations after bee sting have been described. Local reactions, such as pain, wheal, flare, edema and swelling, are common and generally self-limiting. Uncommonly manifestations like vomiting, diarrhea, dyspnea, generalized edema, acute renal failure, anaphylactic shock, myocardial infarction, hypotension, collapse, pulmonary hemorrhage, acute hemorrhagic pancreatitis, and atrial fibrillation may occur. We report a 59 year-old man who sustained ischemic stroke and multi-organ dysfunction following multiple bee stings.

11 January 2023 in The American Journal of Emergency Medicine
Verified
Journal Article
Closed access
MYMetin Yadigaroğlu
Metin Yadigaroğlu
VÇVecdi Vahdet Çömez
Vecdi Vahdet Çömez
YGYunus Emre Gültekin
Yunus Emre Gültekin
YCYasin Ceylan
Yasin Ceylan
HYHüseyin Tufan Yanık
Hüseyin Tufan Yanık
MGMurat Güzel
Murat Güzel

1 August 2014 in The American Journal of Emergency Medicine
Verified
Journal Article
Closed access
MGMurat Güzel
Murat Güzel
ÖSÖmer Salt
Ömer Salt
AEAli K. Erenler
Ali K. Erenler
ABAhmet Baydın
Ahmet Baydın
MDMehmet T. Demir
Mehmet T. Demir
ZDZahide Doganay
Zahide Doganay

1 August 2022 in Current Neurovascular Research
Verified
Journal Article
Closed access
PDF file
MGMurat Güzel
Murat Güzel
MAMuhammet Faruk Akyüz
Muhammet Faruk Akyüz
MYMurat Yücel
Murat Yücel
IGİrEmgül Güngör
İrEmgül Güngör
MYMetin Yadigaroğlu
Metin Yadigaroğlu
HKHüseyin Karataş
Hüseyin Karataş
Background: Secretoneurin is a neuropeptide expressed from endocrine, neuroendocrine, and neural tissues. Our study aimed to investigate whether there was a relationship between secretoneurin levels and the severity of traumatic brain injury (TBI). Methods: Ninety patients aged over 18 years who were admitted to the emergency department with head trauma between April 2020 and October 2020 and 20 healthy volunteers (control group) were included in the study. Patients were divided into three groups according to Glasgow Coma Scale scores: Mild TBI (n=33), moderate TBI (n=28), and severe TBI (n=29). The final status of the patients was evaluated in three groups: exitus, discharge with Glasgow Outcome Scale (GOS) ≤ 3 and discharge with GOS >3. Results: The median secretoneurin levels of patients with severe TBI 31.71 (14.21-70.95) were found to be significantly higher than in those with moderate TBI [17.30 (10.71-69.27) (P=0.025), and patients with moderate TBI had a substantially higher level of secretoneurin than those with mild TBI 11.70 (6-16.25) (P18.13 ng/mL had a sensitivity of 83.87% and a specificity of 77.97% for poor neurologic outcomes (AUC 0.86, 95% CI: 0.77- 0.92). The secretoneurin cut-off value of >20.67 ng/mL had a sensitivity of 90.91% and a specificity of 74.68% for mortality (AUC 0.85, 95% CI: 0.76-0.92). Conclusion: Secretoneurin can be a useful biomarker in diagnosing patients with moderate-tosevere TBI. It may also guide physicians in predicting the clinical outcome of patients with TBI.